The protocol will study the safety and efficacy of using sofosbuvir and ribavirin for the treatment of hepatitis c in patients taking stribild.

The objective of this study is to evaluate the safety, efficacy and pharmacokinetics of sofosbuvir 400mg once daily plus ribavirin 1000-1200 mg daily in HIV-infected patients on fixed dose co-formulation emtricitabine/tenofovir/cobicistat/elvitegravir (Stribild).

Inclusion Criteria:

• 18 years of age or older
• Chronic HCV genotype 1 infection
• Receiving emtricitabine/tenofovir/cobicistat/elvitegravir for at least 8 weeks.
• CD4 count >200 cells/mm3 at screening and no CD4 count <200 in previous 12 weeks
• HIV RNA PCR <50 copies/ml at screening and no HIV RNA PCR > 200 copies/ml in previous 12 weeks

Exclusion Criteria:

• History of integrase inhibitor resistance
• History of integrase inhibitor failure
• Absolute neutrophil counts under 1500/mm3 ( Black/ African Americans <1200/mm3
• Patients with cirrhosis
• Platelet count under 90,000 per cubic millimeter
• Hemoglobin levels <11 gm/dl in women or <12 gm/dl in men
• Previous treatment with a DAA
• Hepatocellular carcinoma
• AFP>100 ng/mL
• hepatitis B virus (HBsAg positive)
• Evidence of decompensated liver disease including, but not limited to, a history of presence of clinical ascites, bleeding varices, or hepatic encephalopathy